IP Library › Granted Patent US 10,047,115
Granted Patent B2
US 10,047,115 · App. 15/543,007 · Granted Aug 14, 2018

Cyclic dinucleotides useful for the treatment of inter alia cancer

Inventors: Keith Biggadike (Stevenage, GB); Aurelie Cecile Champigny (Stevenage, GB); Diane Mary Coe (Stevenage, GB); Deborah Needham (Stevenage, GB); Daniel Terence Tape (Stevenage, GB)
Assignee: GlaxoSmithKline Intellectual Property Development Limited
C07H21/04A61K31/7084
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,047,115
App. No.
15/543,007
Granted
Aug 14, 2018
Kind
B2
Abstract

A compound of formula (I) or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.

Claims (16)

1. A compound of formula (I)

wherein

R 1 is OH and R 2 is NH 2 or R 1 is NH 2 and R 2 is H;

R 3 is OH and R 4 is NH 2 or R 3 is NH 2 and R 4 is H;

One of R 5 and R 6 is F, the other is F or OH,

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 and one or more of pharmaceutically acceptable excipients.

3. A combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 and at least one further therapeutic agent.

4. A compound of claim 1 which is:

or a pharmaceutically acceptable salt thereof.

5. A compound of claim 4 which is:

6. A pharmaceutically acceptable salt of a compound of claim 4 which is:

7. A compound of claim 1 which is:

or a pharmaceutically acceptable salt thereof.

8. A compound of claim 7 which is:

9. A pharmaceutically acceptable salt of a compound of claim 7 which is:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2017
From: BIGGADIKE, KEITH; CHAMPIGNY, AURELIE CECILE; COE, DIANE MARY; NEEDHAM, DEBORAH; TAPE, DANIEL TERENCE
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 043569/0431 →
Priority Claims (1)
GB 1501462.4 · Jan 29, 2015 · national
Continuity (2)
Provisional Application 62262621 · Dec 3, 2015
Related Publication 20180002369A1 · Jan 4, 2018